Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Generics Market Estimated to Reach \338 Billion in 2009: Fuji Keizai
January 21, 2008
- Salagen Improves QOL of Patients with Sjogren's Syndrome
January 21, 2008
- GENERICS NEWS IN BRIEF
January 21, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 21, 2008
- FPMAJ's Pricing System Proposal Not Impossible to Introduce: EAD Director Mr Takeda
January 21, 2008
- Industry Must Quit Yakkasa-Dependent Sales Once for All
January 21, 2008
- Re-pricing Inevitable under Public Health Insurance System: Mr Isobe
January 21, 2008
- Ensure Sustained Growth by Developing Innovative New Drugs: Top Company Leaders
January 21, 2008
- Hire More Ex-Company Employees: Dr Aoki
January 21, 2008
- Takeda, Daiichi Sankyo Files NDAs for Their Future Blockbusters in the US
January 21, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 14, 2008
- NEW PRODUCTS
January 14, 2008
- Pfizer to Conduct PII Study on Glaucoma Treatment from NicOx
January 14, 2008
- AstraZeneca Aims at Sales of \33 Bil. with Drugs for Breast Cancer in 2008
January 14, 2008
- Standard Forms Completed for Clinical Trial Documents
January 14, 2008
- Industry Needs Pricing System That Rewards Innovation: JPMA President Dr Aoki
January 14, 2008
- GMP for Investigational Drugs to Be Amended
January 14, 2008
- JAPhMed to Certify Pharmaceutical Medicine Specialists
January 14, 2008
- REGULATORY NEWS IN BRIEF
January 14, 2008
- Complete Lifting of Ban on Kongyo Shinryo Not Recommended by Council
January 14, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…